Multicenter analytical evaluation of a high-sensitivity troponin T assay

作者：Saenger A K^*; Beyrau R; Braun S; Cooray R; Dolci A; Freidank H; Giannitsis E; Gustafson S; Handy B; Katus H; Melanson S E; Panteghini M; Venge P; Zorn M; Jarolim P; Bruton D; Jarausch J; Jaffe A S

来源：Clinica Chimica Acta, 2011, 412(9-10): 748-754.

DOI：10.1016/j.cca.2010.12.034

• Troponin
• 99th percentile
• High-sensitivity
• Acute myocardial infarction
• Cardiac biomarkers

Background: High-sensitivity cardiac troponin assays are being introduced clinically for earlier diagnosis of acute myocardial infarction (AMI). We evaluated the analytical performance of a high-sensitivity cardiac troponin T assay (hscTnT. Roche Diagnostics) in a multicenter, international trial.
Methods: Three US and 5 European sites evaluated hscTnT on the Modular (R) Analytics E170, cobas (R) 6000, Elecsys 2010, and cobas (R) e 411. Precision, accuracy, reportable range, an inter-laboratory comparison trial, and the 99th percentile of a reference population were assessed.
Results: Total imprecision (CVs) were 4.6-36.8% between 3.4 and 10.3 ng/L hscTnT. Assay linearity was up to 10,000 ng/L and the limit of blank and detection were 3 and 5 ng/L, respectively. The 99th percentile reference limit was 14.2 ng/L (n = 533). No significant differences between specimen types, assay incubation time, or reagent lots existed. A substantial positive bias (76%) exists between the 4th generation and hscTnT assays at the low end of the measuring range (< 50 ng/L). hscTnT serum pool concentrations were within 2SD limits of the mean of means in the comparison trial, indicating comparable results across multiple platforms and laboratories.
Conclusion: The Roche hscTnT assay conforms to guideline precision requirements and will likely identify additional patients with myocardial injury suspicious for AMI.

• 出版日期2011-4-11